CDK4 and hepatocellular carcinoma: These findings are in accordance with our previous results showing that palbociclib, another CDK4/6 inhibitor, improved the efficacy of regorafenib in HCC cells (18), suggesting that CDK4/6 targeting may represent a valuable strategy for enhancing the anti-tumor activity of the anti-angiogenic drugs currently used in the clinic for advanced HCC treatment.